Science & Enterprise subscription

Follow us on Twitter

  • A company designing gene-edited T-cells as cancer therapies stopped its clinical trial of a treatment for multiple… https://t.co/0PktfkzyNH
    about 4 hours ago
  • New post on Science and Enterprise: FDA Halts Off-the-Shelf Engineered T-Cell Trial https://t.co/Fbz7IKCgky #Science #Business
    about 4 hours ago
  • If you dig deep into the Science & Enterprise archives, you'll find this site began posting on 6 July 2010, exactly… https://t.co/eGPudMExsK
    about 20 hours ago
  • New post on Science and Enterprise: Essay – Ten Years and Counting https://t.co/bIFz5ld4g4 #Science #Business
    about 20 hours ago
  • A cocktail of two synthetic antibodies will soon be tested in a clinical trial to prevent against Covid-19 infectio… https://t.co/auyvJKhyBq
    about 23 hours ago

Please share Science & Enterprise

Organ Chip Spin-Off Gains $28M in Venture Funds

Small airway chip

Small airway chip (Wyss Institute, Harvard University)

28 March 2016. A two year-old company developing chip devices that simulate human organs is adding $28 million in venture capital to its treasury. This is the second venture funding round for Emulate Inc., in Boston, a spin-off enterprise from the Wyss Institute for Biologically Inspired Engineering at Harvard University.

Emulate Inc. creates plastic chip devices about the size of USB computer memory sticks with miniaturized collections of human cells and enzymes that mimic the functions of human organs. The technology aims to provide a safer and more reliable medium to test drugs than cell cultures and lab animals. These devices, says the company, recreate micro environments that allow the observation and tracking of drugs with mechanical forces in human organs, interactions with tissue and chemicals in the body, and effects on blood cells including immune system cells.

So far Emulate Inc. designed working models of the lung, intestine, liver, and kidney, is working on skin, eye, and brain systems. The chips can work independently, but can also be linked together to assess interactions on multiple organs or even the entire body at once. The company plans to develop a human emulation system, an integrated, automated, and self-contained set of devices that includes instrumentation and supporting software.

As reported by Science & Enterprise in December 2015, Emulate Inc. collaborated with the Wyss Institute and the pharmaceutical companies Merck and Pfizer, to develop a human airway chip to study asthma and COPD. Science & Enterprise also reported on the company’s founding in July 2014 and its initial venture funding round that raised $12 million.

The latest financing round was provided by new investors OS Fund; Atel Ventures; ALS Finding a Cure, and the Leandro P. Rizzuto Foundation, as well as current investors Hansjörg Wyss, NanoDimension, and Cedars-Sinai Medical Center. Proceeds from the funding round are expected to expand the repertoire of organ chips to kidney, heart, and brain models. The funds will also support expanding the types of disease states simulated on the chips to include cancer, as well as neurodegenerative, intestinal, and infectious diseases.

In addition, the new funds will support the human emulation system launch as a product for labs to run on their own. Emulate Inc. seeks to design the system as a stand-alone product to run without specialized expertise.

Read more:

*     *     *

Please share Science & Enterprise ...

Comments are closed.